OncologyConsults




Head & Neck CME
CME Activities

Appropriate Use of Immune Therapy to Treat Head and Neck Cancer CME Credits: 0.5
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit.
Faculty: David S. Ettinger, MD Expires: 9/7/2018


Integrating Immunotherapy into SCCHN Care: Implications for the Multidisciplinary Oncology Care Team CME Credits: 0.5
While the US Food and Drug Administration approval of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit for patients with head and neck cancer.
Faculty: Young Jun Kim, MD, PhD Expires: 6/15/2020